Honey vs. Sugar in Yogurt: What a Tiny Trial Found

Honey may taste more wholesome than table sugar, but a small clinical trial does not yet show that swapping one for the other turns yogurt into an anti-inflammatory food. In healthy postmenopausal women, four weeks of honey-sweetened Greek yogurt changed one secondary cytokine, IL-33, compared with sugar-sweetened yogurt. The trial found no significant improvement in its primary inflammatory endpoint, IL-23, or in short-chain fatty acids, bile acids, blood lipids, or glucose.

The result is worth understanding because the intervention was practical: sweeten a familiar breakfast with honey rather than cane sugar. But it is an early biomarker finding, not evidence that honey prevents disease, eases symptoms, or meaningfully lowers inflammation.

What the honey-yogurt trial actually tested

Chen et al. (2026) ran a randomized, single-blind crossover trial in 20 healthy postmenopausal women ages 45 to 65 with BMI values between 25 and 30 kg/m². Each participant ate two 150 g servings of plain nonfat Greek yogurt daily for four weeks, then crossed over to the other version after a four-week washout.

The yogurt base stayed the same. Both versions contained probiotic cultures and supplied a daily total of 279 kcal, 28 g protein, 344 mg calcium, and 115 mg sodium. The only planned difference was the sweetener: one tablespoon of clover blossom honey per serving, or an isocaloric amount of cane sugar.

This was a sugar substitution experiment, not a sugar-reduction experiment. The honey arm supplied 42 g of honey daily, or about 34 g per day of added sugar. That exceeded the 25 g daily added-sugar benchmark for women cited by the authors from the American Heart Association. Honey contains compounds beyond sugar, but "natural" does not make 34 g of added sugar disappear into a wellness fog.

The participants also began the study at relatively low cardiometabolic risk. Their average age was 60.1 years, average BMI was 28.4, fasting glucose averaged 99.7 mg/dL, triglycerides 86.5 mg/dL, and HDL cholesterol 67.1 mg/dL. The trial therefore cannot tell us whether the same swap helps women with insulin resistance, obesity, cardiovascular disease, or a high inflammatory burden.

One secondary cytokine changed; the main outcomes did not

The most favorable result involved IL-33, a signaling protein involved in immune activity. During the sugar period, IL-33 rose by 3.85 pg/mL; during the honey period, it fell by 2.56 pg/mL. The adjusted difference between interventions over time was 6.42 pg/mL (95% CI, 0.18 to 12.66; p=0.044). By conventional statistical standards, that secondary comparison was significant.

Its clinical meaning remains uncertain. The paper discusses IL-33 as an alarmin involved in adipose immune homeostasis, not as a validated clinical risk marker for this population. A lower IL-33 value over four weeks does not establish lower disease risk, better health, or less systemic inflammation in a way a patient would feel.

The prespecified primary inflammatory endpoint, plasma IL-23, did not significantly differ by sweetener. The intervention-by-time interaction was 0.346 pg/mL with p=0.056, which falls short of the usual statistical threshold. An exploratory subgroup of 10 women with higher baseline IL-6 showed a significant IL-2 interaction of 1.70 pg/mL (95% CI, 0.19 to 3.21; p=0.028), while IL-33 was not significant in that subgroup (p=0.119). Small subgroup findings can generate useful hypotheses, but they are poor material for a breakfast prescription.

The proposed gut mechanism did not show up

The study measured fecal short-chain fatty acids, including acetate, butyrate, propionate, valerate, and hexanoate. None showed a significant intervention-by-time effect. For example, the difference for butyrate was 413 µg/g (p=0.188), and the difference for propionate was 366 µg/g (p=0.110). Plasma bile-acid interactions were also non-significant. Honey did not improve plasma lipids or glucose compared with matched cane sugar.

Those null results matter because the proposed story depended on honey changing gut-derived metabolites that could then influence inflammation. The trial did not demonstrate that chain of events. The IL-33 result could be real, random, or driven by a pathway the measured metabolites did not capture. This study cannot distinguish among those explanations.

Diet can alter microbial fermentation products when the dietary shift is large enough. In the three-month randomized CARBFUNC trial, a cellular high-carbohydrate diet increased fecal butyrate by 4.97 compared with a refined-carbohydrate comparator (95% CI, 1.71 to 8.23; p=0.003). That finding supports the general reason to measure short-chain fatty acids in nutrition research. It does not validate honey-sweetened yogurt, especially when the direct honey trial found no such change over four weeks.

Plausibility is not proof

Several human studies make the broader biology believable without proving this specific food swap. A randomized trial of Mediterranean-style diet interventions found that gut microbial bile-acid metabolism modified cardiometabolic responses to diet, as reported by Gao et al. (2024). In another randomized crossover study, replacing saturated fat with polyunsaturated fat increased Lachnospiraceae abundance and was associated with lower total cholesterol in healthy adults, according to Telle-Hansen et al. (2022).

Observational work points in the same general direction, with important limits. In 129 overweight adults, higher fiber intake and higher fecal short-chain fatty acid concentrations were associated with lower plasma lipopolysaccharide-binding protein and lower inflammatory markers in Bailey et al. (2023). Because that study was cross-sectional, it cannot show that fiber or short-chain fatty acids caused the lower inflammation. People who eat more fiber often differ in many other ways.

Controlled feeding studies can also detect metabolite changes within broader dietary patterns. A four-period crossover trial by DiMattia et al. (2025) measured changes in gut microbiota and circulating, fecal, and urinary metabolites across Mediterranean-style diets with different lean-beef quantities. These studies show that food choices can affect gut-related biology. They do not turn a null-heavy honey trial into proof of an anti-inflammatory effect.

Why the positive result needs restraint

The direct evidence consists of one trial with 20 completers and four-week intervention periods. That design can detect short-term biomarker movement, but it cannot establish durable effects on cardiovascular risk, inflammatory disease, symptoms, or longevity.

IL-33 was one of many cytokine and metabolite comparisons. The reported p value of 0.044 was nominal, and the extracted results do not indicate a correction for multiple comparisons. When researchers test many outcomes in a small sample, a positive result can arise by chance. The study also reported baseline between-period differences in several short-chain fatty acids and bile acids, plus significant period effects for systolic blood pressure and hexanoic acid. Those features make crossover interpretation less tidy than the yogurt cups suggest.

The honey came from the National Honey Board, and one author disclosed consultancy with Dairy Management Inc. These disclosures do not invalidate the trial. They do make independent replication more valuable.

For now, honey in yogurt is a preference, not an evidence-based inflammation intervention.

The practical verdict

If you enjoy honey in Greek yogurt, this trial gives no reason to think it performed worse than an isocaloric cane-sugar control for these relatively healthy women over four weeks. It also does not provide a clinical reason to add honey for inflammation control. The one significant IL-33 finding deserves follow-up in larger, longer, independently funded trials that prespecify outcomes and measure patient-relevant effects.

For cardiometabolic health after menopause, broader dietary patterns have stronger footing than a sweetener swap. A systematic review of controlled diet trials in postmenopausal women supports studying whole-diet approaches to cardiovascular risk factors. Until stronger honey-specific evidence arrives, prioritize the qualities that make yogurt a useful food in the first place: adequate protein, an overall diet with plenty of fiber-rich plants, and an amount of added sugar that fits your goals.